Recently, it has been reported that PDL1 may be a useful biomarker to differentiate CIS (carcinoma in situ) from microinvasive cancer and, thus, anti-PDL1 therapy may inhibit the progression of CIS to the invasive stage29. Here, CD274 is linked to cancer.